Novo Nordisk’s shares drop 10% after the key ingredient in its blockbuster drugs, Ozempic and Wegovy, fails to show benefits in Alzheimer’s trials. Analysts at J.P. Morgan say this won’t impact the Danish drugmaker’s forecasts, as the market had already viewed the trial as high risk. Consensus expectations included a minor contribution of 7 billion Danish kroner ($1.08 billion) in 2032 sales. Shares hit 2021 levels.

Read more at “Wall Street Journal”

1. The latest jobs report shows that the US economy added 943,000 jobs in July, exceeding expectations. The unemployment rate also fell to 5.4%, the lowest since the start of the pandemic.

2. Apple Inc. reported a 12% increase in revenue for the third quarter, with $81.43 billion in sales. The tech giant’s profits were up 21%, beating analyst forecasts.

3. The FDA has granted full approval to Pfizer-BioNTech’s Covid-19 vaccine, becoming the first in the US to receive such authorization. The move is expected to boost vaccination rates and confidence in the shot.: Health Care Roundup: Market Talk